Fast Company Names egnite, Inc. One of Its Most Innovative Companies in 2024

Fast Company Names egnite, Inc. One of Its Most Innovative Companies in 2024

ALISO VIEJO, Calif. – March 19, 2024 Fast Company, the world’s leading progressive business media brand, announced egnite, Inc. as one of the World’s Most Innovative Companies in their 2024 ranking. egnite, a leading digital health company specializing in artificial intelligence solutions to advance cardiovascular care, stands at the forefront of innovation in the healthcare sector.

The 2024 list showcases businesses pioneering advancements within their industries, setting new standards for innovation and paving the way for future breakthroughs. Among these trailblazers, egnite is recognized for its significant contributions to improving healthcare efficiency and patient outcomes.

In a world where heart disease remains a leading cause of mortality, with over 800,000 annual deaths in the U.S. alone, egnite’s artificial intelligence (A.I.) solutions help physicians reduce variability in care to ensure patients get the right treatment at the right time. In 2023, the company launched several new artificial intelligence technologies focused on helping physicians identify patients with risk for stroke, heart failure, and heart valve disease. Today, clinicians use egnite’s technology to screen and monitor patients, ensuring significant disease is quickly detected and treated before it’s too late.

“Gaps in care may unintentionally delay care for patients with life-threatening cardiovascular diseases. Artificial Intelligence technologies hold the potential to dramatically improve patient care and alleviate burdens on healthcare providers nationwide. Through these innovative solutions, we’re enabling providers to practice top-of-license care and ensure more patients are receiving life-saving therapy,” says Kahla Verhoef, chief product officer of egnite.  

To date, egnite’s technology:

  • Helps providers save 2 lives a day
  • Improves workflow efficiencies by up to 55%.¹
  • Increased life-saving treatment rates by 25%²

egnite’s commitment to advancing healthcare through innovative technologies underscores its position as a leader in the digital health space. As the company continues to leverage its technology to help improve patient care, it remains dedicated to shaping the future of cardiovascular health.

About egnite, Inc.

egnite is a visionary digital health company committed to advancing the health of our society through innovative cardiovascular solutions. egnite uses AI-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions. The company, based in Aliso Viejo, California, partners with leading hospitals and life sciences organizations to transform care delivery for cardiovascular patients. For more information, visit www.egnitehealth.com.

References

  1. Compared to traditional screening methods
  2. Represents median growth from 17 CardioCare sites with baseline data one year after implementing the CardioCare platform.

Related Articles

AI Alliance

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.

Real-World Evidence

Acute Valve Syndrome in Aortic Stenosis

“These findings are extremely important and complementary to the recently presented EARLY TAVR Trial, published in the NEJM. The absence of symptoms was traditionally considered a sign of relative safety. However, this study shows how frequent acute valve syndrome is in patients undergoing AVR, and how patients would benefit greatly

Press

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR) Key Findings Demonstrate 3x Improved Survival for Asymptomatic AS Patients Undergoing AVR versus AS Patients Presenting with Acute Valve Syndrome ALISO VIEJO, Calif. – October 28, 2024 – egnite, Inc., a leading cardiovascular digital